|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||-0.64|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
It was back in April when the Chief Medical Officer of pharma giant Celgene Corporation (NASDAQ:CELG), Dr. Jerome B. Zeldis joined the board of MetaStat Inc. (OTCMKTS:MTST). It was clear from here that something was in the works between the two companies and that perhaps a licensing deal would soon be struck between the two. […]
The state licensure and CLIA certification follows on the heels of studies validating the performance and accuracy of MTST’s fully automated MetaSite Breast assay. In late August MTST announced the automated (i.e.
The study, titled MenaCalc, a Quantitative Method of Metastasis Assessment, as a Prognostic Marker for Axillary Node-Negative Breast Cancer, assessed MenaCalc as a predictor of survival in patients with axillary node-negative (ANN) breast cancer. Axillary lymph nodes are located in the armpit which is typically the first place where breast cancer will spread. ANN means that the cancer has not spread to the lymph nodes which generally relates to a more favorable prognosis. Tumor samples were obtained from eight Toronto hospitals where patients were treated from 1987 to 1993. Of the 403 patients, 332 had no lymphatic invasion while 70 did (data was missing on 1).